Disc Medicine, Inc. 4

Disc Medicine CEO John D. Quisel exercised options for 33,000 shares at $13.50 and sold 33,000 shares of common stock around $78–80 on August 17, 2026 under a Rule 10b5-1 plan.

On August 17, 2026, Disc Medicine, Inc. CEO John D. Quisel exercised a stock option for 33,000 shares of common stock at an exercise price of $13.50 per share and simultaneously sold an aggregate 33,000 shares of common stock in three open market transactions at weighted average prices of $78.1061, $79.1952, and $79.8420 per share, all under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2026. The option exercise (coded “M”) transferred 33,000 shares from derivative to non-derivative holdings, increasing his common stock to 259,064 shares before the sales; subsequent sales of 8,400, 12,712, and 11,888 shares reduced his direct common stock ownership to 226,064 shares, while his remaining option position referenced in the filing shows 91,586 derivative securities outstanding. Based on the reported prices, the gross value of the shares sold is approximately $2.6 million, while the option exercise cost is approximately $445,500, indicating a sizable net monetization event but still leaving a substantial residual equity stake.

Filing Facts

CIK

1816736

Ticker

IRON

Form

4

Source Type

fda

Accession

0001193125-26-355841

Alert Tier

7